Advances in the molecular characterization of leukemic cells have greatly improved the precision of diagnosis and treatment assignment as well as the monitoring of residual disease in both acute lymphoblastic leukemia and acute myeloid leukemia. Currently, specific genetic rearrangements can be identified in as many as 50% of children with either acute lymphoblastic leukemia or acute myeloid le...

Hematologic malignancy is a risk factor for severe coronavirus disease 2019 (COVID-19) in adults; however, data specific to children with leukemia are limited. High-quality infectious adverse event from the ongoing Children's Oncology Group (COG) standard-risk B acute lymphoblastic leukemia/lymphoma (ALL/LLy) trial, AALL1731, were analyzed provide disease-specific estimate of SARS-CoV-2 infecti...

Myeloid/lymphoid neoplasms with FGFR1 rearrangement (MLN-FGFR1) comprise a heterogeneous group of that can present as myeloproliferative neoplasm, myelodysplastic/myeloproliferative acute myeloid leukemia, T or B lymphoblastic leukemia/lymphoma, mixed phenotype leukemia. The overall outcome these is poor, and patients often show cytogenetic evolution gain additional chromosomal abnormalities le...

acute lymphoblastic leukemia is the most common form of pediatric cancer which is categorized into three l1, l2, and l3 and could bedetected through screening of blood and bone marrow smears by pathologists. due to being time‑consuming and tediousness of theprocedure, a computer‑based system is acquired for convenient detection of acute lymphoblastic leukemia. microscopic images areacquired fro...

conclusions our findings indicated that mdm2 40-bp ins/del polymorphism was not associated with all in our iranian population. further studies with larger sample sizes and diverse ethnicities are required to verify our findings. background the human murine double minute 2 (mdm2), an oncoprotein, is the major negative regulator of p53. objectives the purpose of this study was to evaluate the imp...

Osteonecrosis is one of the most common, serious, toxicities resulting from the treatment of acute lymphoblastic leukemia. In recent years, pediatric acute lymphoblastic leukemia clinical trials have used discontinuous rather than continuous dosing of dexamethasone in an effort to reduce the incidence of osteonecrosis. However, it is not known whether discontinuous dosing would compromise antil...

Relapsed acute lymphoblastic leukemia is the most common cause of cancer-related mortality in young people and new therapeutic strategies are needed to improve outcome. Recent studies have shown that heterozygous inactivating mutations in the histone acetyl transferase, CREBBP, are particularly frequent in relapsed childhood acute lymphoblastic leukemia and associated with a hyperdiploid karyot...

The ex vivo sensitivity of pediatric leukemia cells to the proteasome inhibitor bortezomib was compared to 3 next generation proteasome inhibitors: the epoxyketone-based irreversible proteasome inhibitors carfilzomib, its orally bio-available analog ONX 0912, and the immunoproteasome inhibitor ONX 0914. LC50 values were determined by MTT cytotoxicity assays for 29 childhood acute lymphoblastic ...